-
公开(公告)号：US20240342231A1
公开(公告)日：2024-10-17
申请号：US18426803
申请日：2024-01-30
IPC分类号： A61K35/761 , C12N7/00 , C12N15/86
CPC分类号： A61K35/761 , C12N7/00 , C12N15/86 , C07K2319/20 , C12N2710/10034 , C12N2710/10052 , C12N2710/10345
摘要： Compositions and methods for retargeting adenovirus to a cell using chemical dimers are described. In particular, a recombinant adenovirus comprising a nucleic acid comprising a capsid-dimerizing agent binder conjugate and a ligand-dimerizing agent binder conjugate is provided.
-
公开(公告)号：US12116602B2
公开(公告)日：2024-10-15
申请号：US17930943
申请日：2022-09-09
发明人： Liyi Geng , Ping Chen , William S. Brimijoin , Yang Gao
IPC分类号： C12N9/18 , C07K14/00 , C07K14/575 , C12N7/00 , C12N15/86 , A61K35/76 , A61K35/761 , A61K38/00 , A61K38/22 , A61K48/00 , C07H21/04 , C12N15/861 , C12N15/864
CPC分类号： C12N9/18 , C07K14/00 , C07K14/5759 , C12N7/00 , C12N15/86 , C12Y301/01008 , A61K35/76 , A61K35/761 , A61K38/00 , A61K38/2264 , A61K48/00 , C07H21/04 , C12N15/861 , C12N15/8645 , C12N2750/14141 , C12N2750/14143
摘要： This document provides butyrylcholinesterases having an enhanced ability to hydrolyze acyl ghrelin as well as nucleic acids encoding such butyrylcholinesterases. This document also provides methods and materials for treating obesity and/or aggression. For example, methods for administering a nucleic acid encoding a wild-type or mutant butyrylcholinesterase having the ability to hydrolyze acyl ghrelin to a mammal under conditions wherein the level of acyl ghrelin within the mammal is reduced, under conditions wherein the rate of body weight gain of the mammal is reduced, under conditions wherein the mammal's level of aggression is reduced, and/or under conditions wherein the mammal's rate of developing stress-induced tissue damage are provided.
-
公开(公告)号：US20240325314A1
公开(公告)日：2024-10-03
申请号：US18431967
申请日：2024-02-03
发明人： Eddie Yocon Chung
IPC分类号： A61K9/50 , A61K9/00 , A61K9/51 , A61K35/761 , C12N7/00
CPC分类号： A61K9/5068 , A61K9/0019 , A61K9/5184 , A61K9/5192 , A61K35/761 , C12N7/00 , C12N2710/10332
摘要： Disclosed is a nanoparticle comprising an inner core comprising a virus such as AAV8 or lentivirus; and an outer surface comprising a cellular membrane derived from a cell, and process of making thereof. The cellular membrane is derived from for example red blood cells.
-
公开(公告)号：US20240261350A1
公开(公告)日：2024-08-08
申请号：US17927420
申请日：2021-05-20
发明人： Florian Kühnel , Norman Woller , Stefan Kubicka
IPC分类号： A61K35/761 , A61P35/00 , C12N15/86
CPC分类号： A61K35/761 , A61P35/00 , C12N15/86 , C12N2710/10322 , C12N2710/10332 , C12N2710/10343
摘要： Adenovirus for use in anti-tumour therapy which has specificity for tumour cells, especially for tumour cells that have reduced activity levels of the tumour suppressor p53. It is known that the majority of tumours characteristically exhibit reduced activity of the tumour repressor p53. In tumour-bearing patients, the adenovirus provides for an effective cross-presentation of tumour antigens, which can be neoantigens. e.g. having low immunogenicity, and hence supports the induction of tumour-specific immune cells, especially of tumour-specific CD8 T− cells. Further, the adenovirus in tumour patients stimulates the non-specific immune response by NK-cells, preferably both locally and systemically, and the adenovirus improves migration of immune cells. e.g. T-cells. NK-cells, and antigen-presenting cells (APC), e.g. dendritic cells, into the tumour, and the adenovirus improves the maturation of immune cells, especially of APC, and improves the cytolysis of tumour cells by immune cells. The adenovirus has an E4 protein which contains an E4 orf4-encoded protein of one of amino acid sequences SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3.
-
公开(公告)号：US20240252562A1
公开(公告)日：2024-08-01
申请号：US18591746
申请日：2024-02-29
IPC分类号： A61K35/761 , C12N7/00 , C12N15/85 , C12N15/86
CPC分类号： A61K35/761 , C12N7/00 , C12N15/85 , C12N15/86 , C12N2523/00 , C12N2710/10361 , C12N2750/14143 , C12N2750/14151
摘要： The present disclosure generally relates to methods of protecting the genomic integrity and/or biological activity of AAV viral particles in a sample containing both AAV particles and helper virus particles during heat inactivation. The methods include heating, to a temperature greater than or equal to 45° C., a sample containing helper virus particles, AAV particles, and a buffer. The buffer includes a concentration of 10 mM or greater kosmotropic salts and/or a concentration of 10 mM or greater of divalent or trivalent cations.
-
公开(公告)号：US20240252561A1
公开(公告)日：2024-08-01
申请号：US18560539
申请日：2022-05-18
IPC分类号： A61K35/761 , A61P35/00 , C12N7/00
CPC分类号： A61K35/761 , A61P35/00 , C12N7/00 , C12N2710/10022 , C12N2710/10032 , C12N2710/10071
摘要： A method for treating a bone and soft tissue tumor, including administering a conditionally replicating adenovirus having a E1A gene under expression control of a Survivin promoter, to a subject in need thereof. A conditionally replicating adenovirus including a E1A gene under expression control of a Survivin promoter and the conditionally replicating adenovirus is not defective in a E3 region.
-
公开(公告)号：US12023386B2
公开(公告)日：2024-07-02
申请号：US17563633
申请日：2021-12-28
CPC分类号： A61K48/0058 , A61K35/761 , A61K48/0008 , A61P1/16 , C12N9/1051 , C12N15/62 , C12Y204/01017 , C12N2750/14143 , C12N2810/6027 , C12N2830/008
摘要： The invention provides a polynucleotide sequence (e.g., a gene, e.g., DNA or RNA) encoding UGT1A1 (e.g., expressing human UGT1A1). The invention further provides a vector, such as an adeno-associated virus (AAV) vector (e.g., AAV8) having a vector genome including inverted terminal repeat sequences and a UGT1A1 coding sequence operably linked to one or more expression control sequences (e.g., expression control sequences including a liver-specific promoter). Also provided are compositions containing these AAV vectors and methods of treating Crigler-Nijjar syndrome type I, Crigler-Nijjar syndrome type II, and Gilbert syndrome.
-
公开(公告)号：US20240200097A1
公开(公告)日：2024-06-20
申请号：US18511290
申请日：2023-11-16
发明人： Mathieu E. Nonnenmacher , Jinzhao Hou , Wei Wang , Matthew Child , Shaoyong Li
IPC分类号： C12N15/86 , A61K35/761 , C07K14/005 , C12N7/00
CPC分类号： C12N15/86 , A61K35/761 , C07K14/005 , C12N7/00 , C12N2750/14122
摘要： The disclosure relates to compositions, methods, and processes for the preparation, use, and/or formulation of adeno-associated virus capsid proteins, wherein the capsid proteins comprise targeting peptide inserts for enhanced tropism to a target tissue.
-
公开(公告)号：US20240180982A1
公开(公告)日：2024-06-06
申请号：US18284948
申请日：2022-03-24
发明人： Alan PARKER , James DAVIES , Emily BATES
IPC分类号： A61K35/761 , A61P35/00 , C07K14/005 , C12N7/00
CPC分类号： A61K35/761 , A61P35/00 , C07K14/005 , C12N7/00 , C12N2710/10321 , C12N2710/10322 , C12N2710/10332
摘要： The invention concerns a modified low seroprevalence adenovirus: a pharmaceutical composition comprising same; and a method of treating cancer using same.
-
公开(公告)号：US20240165176A1
公开(公告)日：2024-05-23
申请号：US18520513
申请日：2023-11-27
发明人： Jiang LI , Yinghan SU
IPC分类号： A61K35/761 , A61K38/19 , A61K38/20 , A61K38/21 , A61P35/00
CPC分类号： A61K35/761 , A61K38/195 , A61K38/208 , A61K38/217 , A61P35/00 , C12N2710/10022 , C12N2710/10032
摘要： Provided are chimeric oncolytic adenoviruses simultaneously expressing IL-12, IFN-γ, and CCL5, and an application thereof in tumor treatment. A capsid protein hexon of the oncolytic adenovirus is formed from chimerizing hexon sequences of the two serotype viruses Ad5 and Ad48, and a fiber protein is formed from chimerizing fiber sequences of the two serotype viruses Ad5 and Ad11. The chimeric oncolytic adenovirus can activate intrinsic anti-cancer activity of a variety of viral structural proteins, the ability to infect tumor cells is increased while also ensuring that the virus itself avoids interception from pre-existing neutralizing antibodies and adhesion and uptake of hepatocytes, and an effect of killing cancer cells is enhanced.
-
-
-
-
-
-
-
-
-
搜索结果
662 条记录 (耗时 0.032 秒)
